Recombinant follicle-stimulating hormone: gold standard or not?
Recombinant follicle stimulating hormone has been available now for almost 10 years and many couples have benefited from its use. Its clinical efficacy, purity and safety profile have been extensively documented in numerous publications. Because of growing public concerns on the safety of gonadotrophins extracted from human urine, the future will lie in the recombinant technology, which will also enable the design of more convenient tailor-made gonadotrophins.
Out
Henk J
HJ
Organon International, Oss, The Netherlands. henkjan.out@organon.com
D005260:Female; D005300:Fertility Agents, Female / Q000592:standards* / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000235:genetics / Q000592:standards / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000627:therapeutic use; D010062:Ovulation Induction / Q000191:economics / Q000379:methods / Q000592:standards*; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use
D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D007986:Luteinizing Hormone